menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Otsuka`s Taiho pays $400M to buy Swiss ADC partner

    GLOBENEWSWIRE

    Taiho & Cullinan Zipalertinib Meets Primary Endpoint In NSCLC Trial

    PR NEWSWIRE

    Nuntius Partners With Taiho Pharma To Develop Next-Gen mRNA Therapies

    BUSINESSWIRE

    Taiho Ventures Expands Investment Pool to $400 Million

    PR NEWSWIRE

    Taiho Pharma`s Lytgobi (futibatinib) Receives Approval in Europe

    EMA

    Taiho and Phost’in License Agreement on the 1st-in-Class GnT-V Inhi. PhOx430

    PRESS RELEASE

    FDA Approves LONSURF in Combination With Bevacizumab for mCRC

    PR NEWSWIRE

    Taiho`s Lytgobi (futibatinib) Receives Approval in Europe

    EMA

    U.S. FDA Accepts for Priority Review Taiho Onc`s sNDA for Trifluridine/Tipiracil

    PR NEWSWIRE

    Taiho Pharmaceutical Obtains Additional Indication of "Postoperative Adjuvant Chemotherapy for Hormone Receptor-Positive and HER2-Negative Breast Cancer at High Risk of Recurrence" for Oral Anticancer Agent TS-1

    PRESS RELEASE

    Taiho Pharmaceutical Obtain Additional Indication for Oral Anticancer Agent TS-1

    PRESS RELEASE

    Drug Combination Meets Survival Endpoint in Ph III Pivotal Trial With RMCC

    BUSINESSWIRE

    Cullinan, Taiho Pharma Complete Agreement for Collaboration on CLN-081/TAS6417

    GLOBENEWSWIRE

    Taiho, chasing larger rivals, buys back rights to Cullinan cancer drug

    BIOPHARMADIVE

    Taiho pays to claw back licensing rights to lung cancer med

    FIERCEBIOTECH

    Taiho Pharma Obtains Approval to Manufacture and Market Arokaris I.V. Infusion

    GLOBENEWSWIRE

    Remiges Ventures launches new life science incubator

    BIOSPECTRUMASIA

    Taiho Pharmaceutical Submits New Drug Application for NK1 Receptor

    PRESS RELEASE

    Taiho TAS-116, an Oral HSP90 Inhibitor, Shows Significantly Prolonged

    TAIHO

    Taiho signs drug licensing deal with Lung Therapeutics in Japan

    PHARMACEUTICAL-TECHNOLOGY

    Taiho Submits Application for Additional Dosage Administration 5-HT3 Receptor

    PRESS RELEASE

    Arcus Biosciences & Taiho Jointly Announce Taiho’s Exercise Zimberelimab

    BUSINESSWIRE

    KRAS craze sees Merck put $2.5B biobucks down for Taiho, Astex licensing deal

    FIERCE BIOTECH

    Merck Establishes Strategic Oncology Collaboration with Taiho and Astex

    PRESS RELEASE

    Taiho Pharmaceuticals moves US court against Natco on generic cancer drug

    ECONOMICTIMES

    LONSURF®trifluridine/tipiracil Receives Marketing Authorization EU for Patient

    BUSINESSWIRE

    Taiho Pharmaceutical Invests in New Venture Capital Fund

    PRNASIA

    Servier and Taiho Oncology Present Latest LONSURF® (trifluridine/tipiracil) Data

    BUSINESSWIRE

    Taiho antes up $250M for its venture arm it gets serious ‘global oncology’ deals

    ENDPTS

    Seeking global deals, Taiho swells its U.S.-based VC fund to $300M

    FIERCE BIOTECH

    Arcus Announces That Taiho Has Exercised Its Option to Commercialize AB928

    Taiho Oncology Eliminates Co-Pays for Many of the Patients Treated with LONSURF®

    PR NEWSWIRE

    Taiho Pharma Canada, Inc. announces Health Canada approval of LONSURF®

    NEWSWIRE

    Bay Area Startup Arcus Biosciences Lands $307 Million+ Deal With Taiho Pharma

    BIOSPACE

    OSE, Servier ink $10.7M deal to develop autoimmune drug

    FIERCE BIOTECH

    Longitude plots a course to a $525M biotech fund, new Taiho group targets cancer

    FIERCE BIOTECH

    Taiho Pharma Forms Venture Arm in California to Foster Cancer Biotech Start-ups

    BIOSPACE

    CHMP Issues Opinion for LONSURF for Refractory Metastatic Colorectal Cancer

    PR NEWSWIRE

    Soft tissue sarcoma drug approved in Japan

    BIOSPECTRUM ASIA

    Taiho, Servier sign exclusive license agreement to develop and commercialize TAS-102 drug

    NEWS MEDICAL

    Taiho Submits Colorectal Cancer Drug In Europe

    PHARMATIMES

    Speedy US Review for J&J Sarcoma Drug Yondelis

    PHARMA TIMES

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.